Abstract
Background History of Chlamydia trachomatis infection has previously been associated with epithelial ovarian cancer (EOC) in observational studies. We conducted a two-sample univariable Mendelian randomisation (MR) study to examine whether genetically predicted seropositivity to the C. trachomatis major outer membrane protein (momp) D is causally associated with EOC.
Methods MR analyses employed genetic associations derived from UK Biobank as proxies for momp D seropositivity in 25 509 EOC cases and 40 941 controls that participated in the Ovarian Cancer Association Consortium. Findings were replicated using a GWAS meta-analyses of global biobanks including the UK Biobank, FinnGen and BioBank Japan.
Results Genetically predicted momp D seropositivity was associated with overall and high-grade serous EOC risk in inverse-variance weighted (IVW) and MR-Egger univariable MR analysis (odds ratio (OR) 1.06; 95% confidence interval (CI) 1.02—1.10, and OR 1.08; 95%CI 1.01—1.16, respectively). Replication yielded similar results for overall EOC (OR 1.11; 95%CI 1.01—1.22).
Conclusion This MR study supports a causative link between C. trachomatis infection and overall and high-grade serous EOC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a US National Institutes of Health (NIH) grant to SPK (grant number R01CA259058), UK Research and Innovation Future Leaders Fellowship to SPK [grant number MR/T043202/2], and the UK National Health Service Health Education England East of England Foundation School Specialised Foundation Programme for SLP.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data sets used in this study are publicly available at https://gwas.mrcieu.ac.uk/datasets/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data sets used in this study are publicly available at https://gwas.mrcieu.ac.uk/datasets/
